• Tuesday, Mar 02, 2021
  • Last Update : 10:29 pm

Study: Tocilizumab no benefit to severe Covid-19 patients

  • Published at 02:43 pm January 21st, 2021
Covid-19 Patient

The drug blocks a specific part of the body's immune system that can go into overdrive in serious and critical Covid-19 cases.

Treating severely ill Covid-19 patients with the arthritis drug tocilizumab has no clinical benefit, according to the results of a trial stopped early due to an increase in deaths among those receiving it.

The trial, published Thursday in the BMJ medical journal, appeared to contradict earlier studies in which tocilizumab seemed to show promise in reducing the length of hospital stays for some patients.

The drug, a common treatment for arthritis, blocks a specific part of the body's immune system that can go into overdrive in serious and critical Covid-19 cases.

It had been hoped that the treatment could help to tamp down some of the more extreme inflammatory responses that can lead to death.

Researchers in Brazil conducted a randomised control trial among 129 patients with confirmed Covid-19 at nine hospitals.

They were all either receiving oxygen support or mechanical ventilation and had abnormal levels of at least two inflammation-causing chemicals in their blood.

Sixty five patients received tocilizumab plus standard care, while 64 were given standard care alone.

All patients were monitored for 15 days, by which time 18 (28%) in the tocilizumab group and 13 (20%) in the standard care group were either on ventilators or had died.

In all, 17% of the tocilizumab group had died due to acute respiratory failure or multiple organ failure within 15 days, compared to 3% in the control group.

Due to the increased number of deaths in the first group, the trial was stopped early, researchers said.

The results clash with other studies, including one this month - yet to be peer-reviewed - that appeared to show a beneficial effect on organ function and mortality within 21 days of treatment with tocilizumab.

Thursday's research, which has been reviewed by experts,concluded that in patients with severe or critical Covid-19, “tocilizumab plus standard care was not superior to standard care alone in improving clinical status at 15 days and might increase mortality.”

They said the results “raise questions about an anti-inflammatory approach in the treatment of Covid-19” beyond standard steroids.

The authors did highlight some limitations to the research, including a relatively small sample size. However, they said the results were consistent after adjusting for levels of respiratory support needed by patients at the start of the trial. 

This suggests that the findings are accurate, they said.

Facebook 54
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail